PharmaCyte Biotech, Inc.
PMCB · NASDAQ
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.07 | 0.02 |
| FCF Yield | -28.77% | -12.35% | -4.58% | -7.63% |
| EV / EBITDA | 0.75 | 6.47 | 5.47 | 6.34 |
| Quality | ||||
| ROIC | -1.93% | -1.99% | -2.25% | -2.20% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.24 | -0.09 | 0.17 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -91.66% | -104.04% | 51.66% | -182.55% |
| Safety | ||||
| Net Debt / EBITDA | 1.58 | 14.56 | 17.07 | 18.84 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |